Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

394 publications
Année de publication :
Réseaux :

Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines.

Nanomedicine implication in cancer treatment and diagnosis studies witness huge attention, especially with the promising results obtained in preclinical studies. Despite this, only few nanomedicines succeeded to pass clinical phase.

  • Ref: Adv Drug Deliv Rev. 2020 Dec 31:S0169-409X(20)30294-5.
  • Année de publication : 2020
  • Auteurs : Ladaycia A, Loretz B, Passirani C, Lehr CM, Lepeltier E.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence…

Oncotype DX® assay is used to guide therapeutic decisions in early-stage invasive breast carcinoma but remains expensive. Magee Equations (MEs) and Magee Decision Algorithm (MDA) predict the Oncotype DX® recurrence score (RS) on the basis of histopathological parameters.

  • Ref: Hum Pathol. 2020 Nov 24;108:51-59.
  • Année de publication : 2020
  • Auteurs : Remoué A, Conan-Charlet V, Deiana L, Tyulyandina A, Marcorelles P, Schick U, Uguen A.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Can alternative PET reconstruction schemes improve the prognostic value of radiomic features in non-small cell lung…

Purpose: To evaluate the potential benefit of using alternative reconstruction schemes of PET images for the prognostic value of radiomic features.

Methods: Patients (n=91) with non-small cell lung cancer were prospectively included. All had a PET/CT examination before treatment.

  • Ref: Methods. 2020 Nov 14:S1046-2023(20)30251-6.
  • Année de publication : 2020
  • Auteurs : Tankyevych O, Tixier F, Antonorsi N, Filali Razzouki A, Mondon R, Pinto-Leite T, Visvikis D, Hatt M, Cheze Le Rest C.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer.

(Chemo)-radiotherapy (RT) is the gold standard treatment for patients with locally advanced lung cancer non accessible for surgery. However, current toxicity prediction models rely on clinical and dose volume histograms (DVHs) and remain unsufficient.

  • Ref: Radiother Oncol. 2020 Nov 6;155:144-150.
  • Année de publication : 2020
  • Auteurs : Bourbonne V, Da-Ano R, Jaouen V, Lucia F, Dissaux G, Bert J, Pradier O, Visvikis D, Hatt M, Schick U.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

MRI-derived radiomics: methodology and clinical applications in the field of pelvic oncology.

Personalized medicine aims at offering optimized treatment options and improved survival for cancer patients based on individual variability. The success of precision medicine depends on robust biomarkers.

  • Ref: Br J Radiol. 2019 Dec;92(1104):20190105.
  • Année de publication : 2020
  • Auteurs : Schick U, Lucia F, Dissaux G, Visvikis D, Badic B, Masson I, Pradier O, Bourbonne V, Hatt M.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Activity of the human immortalized endothelial progenitor cell line HEPC-CB.1 supporting in vitro angiogenesis.

The human HEPC-CB.1 cell line with many characteristics of endothelial progenitor cells (EPC) was tested for its proangiogenic properties as a potentially therapeutic compound. HEPC-CB.1 cells’ potential to differentiate into endothelial cells was revealed after treating the cells with a mixture of ATRA, cAMP and VEGF, as shown by the reduced expression levels of CD133, CD271 and CD90 antigens, augmentation of CD146 and CD31, and a decrease in cell clonogenicity.

  • Ref: doi: 10.1007/s11033-020-05662-6.
  • Année de publication : 2020
  • Auteurs : Kantor A, Krawczenko A, Bielawska-Pohl A, Duś D, Grillon C, Kieda C, Charkiewicz K, Paprocka M
  • Réseaux : Réseaux: « Immunothérapies » & « Niches et Epigénétique des Tumeurs »
Lire la publication

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological…

Background: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma.

Objectives: To provide an overview of the management of the French Stage III melanoma population after complete lymph node resection prior to new adjuvant therapies.

  • Ref: doi: 10.1684/ejd.2020.3848.
  • Année de publication : 2020
  • Auteurs : Dalle S, Varey E, Nguyen JM, Dupuy A, Montaudie H, Lesage C, Mortier L, Leccia MT, Skowron F, Celerier P, Meyer N, Dutriaux C, Dalac-Rat S, Khammari A, Lebbe C, Dréno B.
  • Réseaux : Réseaux: « Immunothérapies » & « Hub Oncologie 4.0
Lire la publication

Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic…

The imbalance between BCL-2 homologues and pro-death counterparts frequently noted in cancer cells endows them with a cell autonomous survival advantage. To eradicate ectopic cells, inhibitors of these homologues (BH3 mimetics) were developed to trigger, during anticancer treatment, full activation of the canonical mitochondrial apoptotic pathway and related caspases.

  • Ref: doi: 10.3390/biom10081109
  • Année de publication : 2020
  • Auteurs : Barillé-Nion S, Lohard S, Juin PP.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs » & « Cancers des Tissus Hormono-dépendants »
Lire la publication

Biomarkers of tumor invasiveness in proteomics (Review).

Over the past two decades, quantitative proteomics has emerged as an important tool for deciphering the complex molecular events involved in cancers. The number of references involving studies on the cancer metastatic process has doubled since 2010, while the last 5 years have seen the development of novel technologies combining deep proteome coverage capabilities with quantitative consistency and accuracy.

  • Ref: doi: 10.3892/ijo.2020.5075
  • Année de publication : 2020
  • Auteurs : Pouliquen DL, Boissard A, Coqueret O, Guette C.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs » & « Cancers des Tissus Hormono-dépendants »
Lire la publication

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative…

This prospective study evaluated the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)-negative, carcinoembryonic antigen (CEA)-positive metastatic breast cancer, compared with CT…

  • Ref: doi: 10.2967/jnumed.119.236000
  • Année de publication : 2020
  • Auteurs : Rousseau C, Goldenberg DM, Colombié M, Sébille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Chauvet AF, Fresnel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodéré F.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies » & « Cancers des Tissus Hormono-dépendants »
Lire la publication